By David Bautz, PhD
NASDAQ: SNGX
READ THE FULL SNGX RESEARCH REPORT
Business Update
Evaluating Strategic Options
Soligenix, Inc. (NASDAQ:SNGX) is continuing to evaluate strategic alternatives following the discontinuation of HyBryte™ for the treatment of cutaneous T cell lymphoma (CTCL). As previously reported, the Data Monitoring Committee recommended halting the confirmatory Phase 3 FLASH trial for futility following an interim efficacy analysis in April 2026. After reviewing the results and the program’s remaining development prospects, management elected to terminate HyBryte development in June 2026. Following this decision, management has indicated that it is continuing to evaluate potential partnerships, licensing arrangement, merger and acquisition opportunities, and other strategic alternatives.
Soligenix’s remaining pipeline consists of SGX945 (dusquetide), an innate defense regulatory being developed for recurrent aphthous ulcers associated with Behcet’s disease. The Phase 2a proof-of-concept study that was completed in June 2025 showed beneficial effects in seven of eight patients, with improvements potentially persisting beyond the four-week treatment period. The company is also continuing development of SGX302, a topical formulation of hypericin for mild-to-moderate psoriasis, for which Phase 2a results showed improvement in psoriasis lesions while being well tolerated.
The Public Health Solutions segment is another potential source of strategic value. The portfolio includes RiVax®, a ricin toxin vaccine candidate, and the ThermoVax® heat-stabilization platform, which is being applied to vaccine candidates targeting ricin toxin and filoviruses, including Ebola and Marburg.
Financial Update
On November 6, 2026, Soligenix announced financial results for the third quarter of 2026. The company reported no revenue for the third quarters of 2026 or 2025. R&D expenses for the third quarter of 2026 were $0.4 million, compared to $1.6 million for the third quarter of 2025. The decrease was primarily due to decreases in costs associated with the terminated FLASH2 trial and related HyBryte™ development activities. G&A expenses were $1.0 million for the third quarters of both 2026 and 2025.
Soligenix exited the third quarter of 2026 with approximately $9.0 million in cash and cash equivalents. We estimate this is sufficient to fund operations into the second quarter of 2028. As of October 30, 2026, Soligenix had approximately 23.4 million shares outstanding, and when factoring in stock options and warrants, a fully diluted share count of approximately 31.3 million.
Conclusion
For now, Soligenix appears to be in a transitional period, with management attempting to preserve the value of its remaining assets while evaluating opportunities to restructure or reposition the business. The company has cash sufficient to fund operations into the second quarter of 2028, providing time to evaluate all opportunities. The company’s ability to maintain its Nasdaq listing is also an important consideration as it pursues these alternatives. With no changes to our model, our valuation remains at $1.25 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.